ASCO GU 2016
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- January 21, 2016
- 1 min read
Research on prostate cancer shows that for patients who have undergone prostatectomy, follow-up investigations indicate that radiotherapy combined with Orally Disintegrating Tablets (OD tablets) is effective. Data sourced from ASCO GU 2016.
Key highlights include:
-
Clinical trial results for the addition of OD tablets following radiotherapy in patients who had their prostate removed.
-
The 10-year survival rate was higher in the OD tablet group due to a lower rate of metastasis.
-
Cardiac side effects were approximately twice as common, ranging from 2-3% to 4-6%.
Related data can be found at: http://meetinglibrary.asco.org/content/157474-172
#Prostate Cancer
Compliance: "Formerly certified by Japan's Ministry of Foreign Affairs and METI as an international medical visa guarantor (B-066)."
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4